In millions, except per share items | Mar-31-18 | Dec-31-17 | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 |
| 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Revenues: |
Impax Generics | 83.1 | 112.9 | 151.1 | 150.9 | 134.1 | 139.2 | 175.3 | 121.7 |
Impax Specialty Pharma | 59.2 | 70.0 | 55.3 | 51.2 | 50.3 | 59.2 | 52.6 | 50.9 |
Total revenues | 142.4 | 182.9 | 206.4 | 202.1 | 184.4 | 198.4 | 227.9 | 172.6 |
Revenue growth [+] | -22.8% | -7.8% | -9.4% | 17.1% | -18.2% | -29.7% | 3.1% | -19.4% |
Impax Generics | -38.0% | -18.9% | -13.8% | 24.0% | -21.1% | -38.6% | -3.0% | -30.3% |
Impax Specialty Pharma | 17.8% | 18.2% | 5.1% | 0.6% | -9.3% | 7.1% | 30.1% | 28.8% |
Cost of goods sold | 112.1 | 126.5 | 158.7 | 129.7 | 120.2 | 129.0 | 136.9 | 98.1 |
Gross profit | 30.3 | 56.4 | 47.7 | 72.4 | 64.2 | 69.4 | 91.0 | 74.5 |
Gross margin | 21.3% | 30.9% | 23.1% | 35.8% | 34.8% | 35.0% | 39.9% | 43.2% |
Selling, general and administrative [+] | 57.3 | 64.0 | 53.6 | 51.6 | 47.1 | 57.6 | 55.0 | 44.9 |
General and administrative | | 64.0 | | | | 57.6 | | |
Research and development | 12.3 | 15.7 | 15.8 | 26.8 | 22.5 | 20.5 | 20.1 | 20.8 |
Other operating expenses | 85.5 | -380.0 | 16.1 | -10.7 | 46.4 | -293.6 | 288.6 | 4.4 |
EBITDA [+] | -106.9 | 380.8 | -6.4 | 32.8 | -26.1 | 310.1 | -246.1 | 25.1 |
EBITDA growth | 310.3% | 22.8% | -97.4% | 30.8% | -148.5% | 170.7% | -629.9% | -32.9% |
EBITDA margin | -75.1% | 208.2% | -3.1% | 16.2% | -14.1% | 156.3% | -108.0% | 14.5% |
Depreciation | 3.5 | 7.2 | 14.4 | 10.9 | 8.6 | 8.4 | 8.3 | 8.3 |
EBITA | -110.4 | 373.6 | -20.8 | 21.9 | -34.6 | 301.8 | -254.4 | 16.8 |
EBITA margin | -77.6% | 204.2% | -10.1% | 10.8% | -18.8% | 152.1% | -111.6% | 9.7% |
Amortization of intangibles | 14.5 | 16.9 | 17.0 | 17.3 | 17.2 | 16.9 | 18.4 | 12.4 |
EBIT [+] | -124.9 | 356.7 | -37.8 | 4.6 | -51.8 | 284.9 | -272.8 | 4.4 |
EBIT growth | 141.1% | 25.2% | -86.1% | 5.1% | -236.5% | 201.1% | -1089.7% | -75.6% |
EBIT margin | -87.7% | 195.0% | -18.3% | 2.3% | -28.1% | 143.6% | -119.7% | 2.5% |
Non-recurring items [+] | | 663.3 | -0.8 | 11.9 | | 548.8 | -0.1 | |
Asset impairment | | 664.9 | -0.8 | | | 541.7 | -0.1 | |
Loss (gain) on sale of assets | | 5.4 | | 11.9 | | | | |
Loss on contingent liability | | -31.0 | | | | | | |
Interest expense, net [+] | 13.7 | 12.4 | 13.3 | 13.2 | 13.2 | 11.7 | 10.9 | 8.1 |
Interest expense | 13.7 | 13.0 | 13.6 | 13.4 | 13.2 | 12.5 | 11.1 | 8.5 |
Interest income | | 0.6 | 0.3 | 0.2 | | 0.9 | 0.2 | 0.3 |
Other income (expense), net [+] | 0.3 | 9.0 | -2.1 | -0.5 | -2.5 | 4.5 | -0.4 | -0.2 |
Gain (loss) on sale of assets | -0.4 | | | | | | | |
Litigation settlement | 85.5 | | | | 1.1 | | | |
Gain (loss) on debt retirement | | | | | -1.2 | | | |
Change in value of contingent liability | | 7.1 | -6.3 | | | | | |
Other | 0.7 | 1.1 | 0.4 | -10.0 | -1.3 | -1.6 | -0.2 | -0.2 |
Pre-tax income | -138.2 | -310.1 | -52.4 | -20.9 | -67.5 | -271.0 | -283.9 | -4.0 |
Income taxes | -7.3 | -9.0 | -3.0 | -0.5 | 30.9 | 8.6 | -104.5 | -1.2 |
Tax rate | 5.3% | 2.9% | 5.8% | 2.5% | | | 36.8% | 31.6% |
Net income | -130.9 | -301.1 | -49.4 | -20.4 | -98.4 | -279.6 | -179.3 | -2.7 |
Net margin | -92.0% | -164.6% | -23.9% | -10.1% | -53.4% | -140.9% | -78.7% | -1.6% |
|
Basic EPS [+] | ($1.81) | ($4.18) | ($0.69) | ($0.28) | ($1.37) | ($3.91) | ($2.51) | ($0.04) |
Growth | 31.8% | 6.8% | -72.7% | 648.5% | 833.5% | -2483.5% | -590.9% | 42.2% |
Diluted EPS [+] | ($1.81) | ($4.18) | ($0.69) | ($0.28) | ($1.37) | ($3.91) | ($2.51) | ($0.04) |
Growth | 31.8% | 6.8% | -72.7% | 648.5% | 833.5% | -2565.2% | -611.7% | 42.2% |
|
Shares outstanding (basic) [+] | 72.3 | 72.1 | 71.9 | 71.8 | 71.6 | 71.5 | 71.3 | 71.1 |
Growth | 0.9% | 0.9% | 0.8% | 1.0% | 1.3% | 2.7% | 2.2% | 2.5% |
Shares outstanding (diluted) [+] | 72.3 | 72.1 | 71.9 | 71.8 | 71.6 | 71.5 | 71.3 | 71.1 |
Growth | 0.9% | 0.9% | 0.8% | 1.0% | 1.3% | -0.8% | -2.0% | 2.5% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |